Skip to content
  • About
  • Board
  • News
  • Sign Up
  • Contact

Visit

vjoncology logo
VJHemOnc
Logo
  • Home (current)
  • Diseases
    CLL
    Multiple Myeloma
    Myeloproliferative Neoplasms
    ALL
    AML
    Lymphoma
    View all Diseases
  • Topics
    Transplantation
    Measurable Residual Disease
    CAR-T & Cellular Therapy
    Pharmacy
    Nursing
    Supportive Care
    View all Topics
  • Conferences
    MPN Advances Day
    2019
    iwCAR-T
    2019
    COSTEM
    2019
    ESMO
    2019
    iwCLL
    2019
    IMW
    2019
    View all Conferences
  • Features
  • Podcasts
    • About
    • Board
    • News
    • Sign Up
    • Contact

Venetoclax

3:59
The challenges of post-MPN AML
Steven Knapper
2:41
R/R CLL: combination therapy and tailored treatment
Lydia Scarfò et al.
2:53
MURANO: outcomes after the end of treatment
John Seymour
2:41
Comparing CLL regimens with MRD
John Seymour
2:27
The MURANO study: key findings
John Seymour
3:11
Overcoming resistance to BTK inhibition in CLL
Jennifer Woyach
2:07
Real-world evidence of venetoclax vs ibrutinib vs idelalisib
Anthony Mato
1:11
Florence Cymbalista: iwCLL 2019, key points
Florence Cymbalista
1:27
Frontline therapies for treatment naive CLL patients
Danielle Brander
1:43
Predicting TLS in venetoclax-treated CLL patients
Anthony Mato
3:48
Predicting suboptimal response through intermediate MRD
Andrew Rawstron
5:46
MRD: standardization and application
Andrew Rawstron
4:14
Predicting resistance in CLL patients
Danielle Brander
1:53
MRD assessment in the era of novel therapies for CLL
Carol Moreno
3:45
MRD: a prognostic marker in targeted therapy
Talha Munir
2:35
MRD determinations in venetoclax treatment of CLL
Nicolas Martinez-Calle
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 23
  • Next
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Continue

Please enter your details if you would like to receive the latest hemonc news and updates

Sign up
Disease Channels
  • CLL
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • ALL
  • AML
  • Lymphoma
  • View all
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up
mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJHemOnc logo
The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy